Brief: Dexcom Says Use Of Dexcom G7 Leads To Improvement In Glucose Control In People With Type 2 Diabetes Not Using Insulin Versus Routine Care Control Group
06/06/2026 19:45
BRIEF-Dexcom Says Use Of Dexcom G7 Leads To Improvement In Glucose Control In People With Type 2 Diabetes Not Using Insulin Versus Routine Care Control Group June 6 (Reuters) - Dexcom Inc DXCM.O:
DEXCOM: USE OF DEXCOM G7 LEADS TO IMPROVEMENT IN GLUCOSE CONTROL IN PEOPLE WITH TYPE 2 DIABETES NOT USING INSULIN VERSUS ROUTINE CARE CONTROL GROUP
DEXCOM: CONNECT STUDY SHOWED CLINICALLY SIGNIFICANT REDUCTION IN A1C WHEN USING DEXCOM G7 WITH VARIOUS COMBINATIONS LIKE METFORMIN, GLP-1S SGLT2S
DEXCOM: AVERAGE 1.6% A1C REDUCTION WITH DEXCOM G7 FROM BASELINE MEAN A1C OF 8.8%
DEXCOM: IN PARTICIPANTS USING GLP-1S, USING DEXCOM G7 RESULTED IN 1.4% REDUCTION IN A1C VERSUS 0.2% IN CONTROL GROUP
DEXCOM: SIX-MONTH EXTENSION PHASE OF CONNECT RANDOMIZED CONTROLLED TRIAL IS CURRENTLY BEING CONDUCTED
Source text: [ID:]
Further company coverage: DXCM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DexCom
See all newsU.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
FDA clears first over-the-counter glucose monitor for children
Brief: FDA Clears For Marketing Dexcom's Stelo Glucose Biosensor System For Children
Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction
U.S. RESEARCH ROUNDUP- Apple, Lennar, Toll Brothers